The core technology of ImStem Biotechnology Inc. has recently been granted the patent authorization of the national patent office of Japan and Australia.
The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
The U.S. Patent and Trademark Office has issued a patent for human embryonic stem cell derived mesenchymal stem cells, called hES-T-MSC or T-MSC, and for their method of production.
ImStem Biotechnology, Inc.(ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.
ImStem Biotechnology, (ImStem) announced today that Dr. Hongkui Deng, Ph.D. has been appointed to the Company's Scientific Advisory Board.